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Abstract
Objective: To analyze effects of multidisciplinary pain rehabilitation programs with different 
dosages; care as usual (CAU) versus care as usual short form (CAU-SF).
Methods: A single blinded, 2 armed, randomized controlled trial, with non-inferiority design 
was performed. All patients with chronic musculoskeletal pain referred to an outpatient 
multidisciplinary pain rehabilitation program were eligible for this study. Only dosage in weeks 
differed between the 2 groups, content was similar. The pain disability index (PDI) was the primary 
outcome measure. Four points difference on PDI was applied as non-inferiority margin. Treatment 
effects within groups were expressed in standardized mean difference (SMD) and effect sizes (ES) 
were calculated between groups.
Results: Both groups improved signiﬁ cantly on PDI (CAU: -10.8, CAU-SF: -8.3). Frequent extension 
of CAU-SF leads to limited contrast in dosage between groups. The 2.5 points difference on PDI 
falls within the non-inferiority margin but the conﬁ dence interval (CI) (-2.2 to 7.3) exceeded it. 
SMDs of CAU and CAU-SF were 0.8 and 0.7 respectively. ES was 0.2. 
Conclusions: Reduction of dosage of pain rehabilitation programs did not lead to non-inferior 
mean results. Difference in means showed non-inferiority but CI exceeded both the upper and 
lower border of the non-inferiority margin. The results of this trial are inconclusive.
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Introduction
Multidisciplinary Pain Rehabilitation Programs (PRPs) are recommended for patients with chronic 
low back pain (CLBP) 1. They aim to reduce disability, distress and use of health care services 
by education of physical, psychological and practical techniques to improve function, work 
participation and health related quality of life 2. Multidisciplinary programs are effective for 
patients with chronic musculoskeletal pain (CMP) 1,3,4.
Across pain rehabilitation centres nationally and internationally, there is much diversity in content 
and dosage of PRPs. Health care systems aim for the best treatments based on available evidence. 
However, there is paucity of evidence about the inﬂ uence of dose on effects of PRP. In a recent 
systematic review 5, no randomized controlled trials (RCTs) were identiﬁ ed that were designed to 
analyse effects of differences in dose variables on outcome of PRPs. Additionally no studies were 
identiﬁ ed with the primary objective to analyze the association between dose and effect of PRP. 
If PRPs optimal dosage is known, this may beneﬁ t patients and could reduce direct or indirect 
costs. If similar effects are achieved with a shorter program, this could lead to earlier reduction of 
disability, regaining quality of life, and sooner participation in daily life, and minimize direct and 
indirect costs associated with PRP. Employers could also beneﬁ t from earlier return to work (RTW) 
for patients with work productivity loss, rehabilitation centres can reduce waiting lists and overall 
it can improve efﬁ ciency of care. Additionally shorter programs are also attractive for health care 
insurers and society as a result of reducing direct and indirect costs.
The aim of this study was to analyze differences in effects of PRPs with different duration: care as 
usual (CAU) and PRP short form care as usual (CAU-SF) in a non-inferiority design. CAU-SF was 
hypothesized to be non-inferior to CAU in an outpatient pain rehabilitation setting. 
Methods
Design
The study is a single blinded, 2 armed, RCT, with a non-inferiority design. The RCT took place 
at the University Medical Centre Groningen (UMCG), Department of Rehabilitation Medicine, 
Centre for Rehabilitation, location Beatrixoord Haren. The Medical Ethics Committee of the 
UMCG approved the study protocol [NL30094.042.11]. Trial registration: international clinical 
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Deﬁ nitions
Because dosage variables are relatively new to the scientiﬁ c ﬁ eld of PRP, we have deﬁ ned dosage 
related terms for this study. Duration means the total length of PRP and is expressed in weeks. 
Contact hours are the total amount of hours that a patient spends with his therapist during PRP. 
Participants
All patients with CMP referred to an outpatient PRP at the Centre for Rehabilitation, UMCG, 
between September 2011 and October 2013 were potential participants for this study. This 
centre provides PRPs with duration of 8, 12, 16 or 20 weeks. Patients were eligible for the study 
when: 1. They were admitted for a 12, 16 or 20 week PRP; 2. they had CMP for more than three 
months without a speciﬁ c pathological cause; 3. they experienced CMP induced disability; 4. 
social and psychological factors were complex and were assumed to be relevant in maintaining 
CMP induced disability 2; 5. they were willing to stop other treatments for CMP during PRP (except 
pain medication); 6. they were 18 years or older; 7. they were motivated to participate in PRP 
and 8. they were willing to participate in the study and signed informed consent. Patients were 
excluded when: 1. they were referred to the 8 weeks PRP; 2. they were unable to understand 
the Dutch language; 3. they had co morbidities such as heart failure, rheumatoid arthritis, or 
psychiatric disorders preventing a PRP.
Interventions
Common features of CAU and CAU-SF
The objectives of CAU and CAU-SF were the same and the content was similar; both treatments 
were outpatient, multidisciplinary PRPs aimed to decrease CMP related disability, optimize 
participation and increase quality of life. PRP is intended to coach patients to self manage their 
pain and disability. The rehabilitation team consisted of rehabilitation physicians, occupational 
therapists (OTs), physiotherapists (PTs) and psychologists (PSYs). The PRP, based on cognitive 
behavioural principles, consisted of pain education, for example regarding differences between 
nociceptive and chronic pain. Patients were counselled to reﬂ ect on their pain management 
strategies (avoiding pain) and how these strategies could be changed into other management 
strategies (pain coping, alternating physical activity and rest and gradually increasing activities). 
Each patient set individual treatment goals. PTs applied exercise programs and sports activities, 
to improve patients’ conﬁ dence in movement and reduce pain-related fear, improve activity level, 
and physical functioning. OTs assessed current activities and patterns in daily living and educated 
patients how activities could be changed into, healthy activity levels and patterns. PSYs coached 
patients in understanding and dealing with the social and emotional impact of pain in daily life, 
pain beliefs, barriers for behaviour change and coached patients how to cope with pain. The 
rehabilitation physicians were responsible for the medical diagnosis and interventions (if any) and 
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After the rehabilitation physician considered patients to be eligible for PRP, they were invited for 
an intake procedure, consisting of an interview by an OT, a PT and a PSY. These interviews were 
aimed at admitting a patient to PRP or not, and to formulate a treatment plan. If the patient was 
admitted to PRP, based on the assessments during intake, the team (rehabilitation physician, OT, 
PT, PSY) determined the required duration of 8, 12, 16 or 20 weeks based on assessment of the 
complexity of the physical, social and personal situation of the patient, motivation and ability to 
change behaviour. The team who determined treatment duration consisted of professionals with 
on average 9 years of experience in pain rehabilitation.
PRP consisted of OT sessions, 30 minutes, 2 times a week, PT sessions, 30 to 60 minutes, 2 
times a week and PSY sessions, 60 minutes, once a week. The session frequency of OT and 
PT reduced to once a week, the PSY sessions reduced to once every 2 weeks, based on the 
frequency protocols per duration. All sessions were delivered in a individual setting. For clinical 
reasons, the duration in weeks of PRP could be adapted (extended or shortened) in CAU and 
in CAU-SF, depending on the progression of the patient. Duration could be extended when 
additional coaching was needed to decrease in disability during the extra weeks of PRP. Duration 
was shortened when treatment goals were achieved earlier than expected, when the patient 
demonstrated continued lack of progress, or when the patient stopped the treatment, because it 
did not match patient expectations or reasons not related to the program (for instance holidays). 
Extending or shortening of the duration of PRP was based on agreement between the patient and 
the PRP team and decided by the rehabilitation physician. Reasons for extending or shortening 
PRP were registered.
The difference between CAU and CAU-SF was the duration (in weeks) of PRP proposed to the 
patients after the randomization procedure. Differences in duration will also result in differences 
in contact hours. Patients allocated to the CAU group received 12, 16 or 20 weeks of PRP as 
proposed after the intake procedure. Patients allocated to the CAU-SF group received a 4 week 
shortened form of PRP than proposed (which will result in approximately 10 fewer contact hours 
on average). Thus patients in CAU-SF received 4 weeks less than proposed after intake. Patients 
allocated to 8 weeks of PRP in CAU were excluded because the treatment team thought it would 
not be feasible to offer PRP in 4 weeks with frequencies twice a week.
Outcomes
The primary outcome variable was self-reported disability assessed with the Pain Disability Index 
(PDI) 6. The questionnaire consists of seven items related to work, leisure and activities of daily life 
each item is scored on an 11-point scale (0 indicating no disability and 10 indicating maximum 
disability). The total scale ranges from 0 to 70. The high correlation between the PDI and Oswestry 
Disability Index (r=0.83) indicates good validity. Test-retest reliability is high (ICC=0.91) 7. Minimal 
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The secondary outcome variable, quality of life, was measured with the Euroqol 5D-5L (EQ5D-5L; 
scale range -0.329 to 1.000) 9. The EQ-5D-5L assesses 5 dimensions (mobility, self-care, usual 
activities, pain/discomfort, anxiety/depression) of health on a 5 point scale: no problems, slight 
problems, moderate problems, severe problems, and extreme problems. The overall health is 
assessed on a 0-100 visual analogue scale of 20 cm (EQ-5D-VAS). A higher score indicates a 
better overall health state. The minimally clinical important difference (MCIC) was 10.5 points for 
the EQ-5D VAS and 0.03 points for the 5 dimensions of the EQ-5D-3L 10. The EQ-5D-5L version is 
based on the EQ-5D-3L version. The 5L version demonstrates improved discriminatory power 11, 
but the exact MCIC for this version has not been examined (yet).
Sample size
Sample size was calculated using the group sequential non-inferiority criterion. The standard 
deviation (SD) on PDI scores in CAU was 11. The non-inferiority margin was calculated as 40% 
of the mean change on PDI scores in CAU, which was 10 points, thus the non-inferiority margin 
was set at 4 points. For group sequential non-inferiority design an alpha of 0.045 and power of 
0.8 was used. Using PASS software, these data gave an estimation of 124 patients needed per 
arm and 248 patients in total. Including 10% drop-outs, 276 patients should be included for the 
study.
Randomization
After determination of PRP duration by the team and after obtainment of informed consent, 
patients were randomized by an independent person. Patients were stratiﬁ ed on work status 
(paid work or unpaid/no work), resulting in 2 strata. For each stratum blocks of 6 were used. 
Sequentially numbered, sealed, opaque envelopes were used for each stratum.
Blinding
Patients were blinded for intervention. Before inclusion, they were informed about duration 
of CAU, which could be 8, 12, 16 or 20 weeks. Patients were explained that a duration was 
proposed by the team based on the assessment results. Furthermore, they were informed about 
the experiment of 4 weeks shortening duration. They were unaware of the treatment duration 
they supposed to receive in CAU, and, therefore, they were blinded of allocation to CAU or CAU-
SF. Patients were outcome assessor for outcome measurements; they were blinded for T0 scores. 
Rehabilitation physicians, OTs, PTs and PSYs could not be blinded for intervention for the 20 
weeks duration because this part only exists in the CAU group. Eight week PRPs could be CAU-SF 








































Dosage of PRP: A RCT  |  63
4
Analyses
An interim analysis was performed halfway the inclusion period. This enabled us to recalculate 
the a priori sample size based on trial data, as opposed to assumptions (a priori). Additionally, 
based on a-priori stopping rules, it was decided that the trial would be stopped if more than 25% 
of the PRPs in the CAU-SF were extended or if the difference in means on PDI between CAU and 
CAU-SF was more than 4 points. Differences in mean PDI scores were tested by one sided t-test. 
In consultation with a statistician, a priori it was decided to split the alpha of 0.05 in 0.005 and 
calculate a two-sided 99% conﬁ dence interval (CI) for the interim analysis, and 0.045 with a two-
sided 91% CI for ﬁ nal analyses. Because the study was stopped preliminarily, however, only one 
analysis was performed for which we used a two-sided 95% CI approach.
Means and SD’s of primary outcome are presented for CAU and CAU-SF group. All statistical 
analyses were performed according to an intention to treat analysis and a per protocol analysis. 
A CI approach was used to interpret non-inferiority (Figure 1). For PDI and EQ5D scores, 95% 
2-sided CIs were used in the ﬁ nal analyses. Non-inferiority was established when the difference in 
means was less than 4 (Figure 1). Treatment effects within groups were expressed in standardized 
mean difference (SMD): (meanchange/ SDchange). Effect sizes (ES) were calculated between groups 
(meanchange intervention group - meanchange control group)/ SDPooled 
12. Interpretation of SMD and ES: <0.10 no 








Superior Equivalent Non Inferior Inferior 
2.53 -2.2 7.3 
C1 
Figure 1 Illustration of the phenomenon of non-inferiority testing
The dotted horizontal lines represent the theoretical width of the Conﬁ dence Intervals (CI) of the differences 
in means between experimental group and control group. If the CI lies left of 0: (A) the experimental group is 
superior to the control group. If CI lies left of 4 (B1, B2, B3) the experimental group is non inferior. If CI includes 
4 (C2) non inferiority is inconclusive. If CI lies is right to 4 the experimental group is inferior (D). 
The statistical analyses of the differences between groups resulted in line C1 with conﬁ dence intervals for -2.2 
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Results
Patient characteristics and trial ﬂ ow
Patients were recruited out of an estimated sample of 694 patients, admitted for PRP between 
September 2011 and October 2013. In total 257 (37%) were eligible after signing informed 
consent. Reasons for non-participation were for example: planning misunderstandings, trial 
participation was of low priority and thus forgotten to sign informed consent, unwilling to 
participate in a trial. Interim analyses (October 2013) revealed that in 36% of the patients in 
the CAU-SF PRP was extended. Based on the a priori stopping rules, the study was stopped 
directly after the interim analyses. At that point, n=201 (102 CAU, 99 CAU-SF) patients were 
randomized (Figure 2). In accordance with the rules of the METC, 30 patients, who were enrolled 
in the trial, were given the possibility to receive the admitted treatment duration and therefore 
these patients were excluded from analyses. Analyses were performed for 153 patients who had 
completed PRP: 81 in CAU and 72 in CAU-SF. The majority of patients experienced pain for more 
than 1 years. The most prevalent diagnoses were chronic back pain (42%), chronic neck pain 
(19%), widespread pain (9%) and ﬁ bromyalgia (7%). Patients who completed the study differed 
signiﬁ cantly on work status and welfare status, compared to those who did not complete the 
study (Table 1). 
Assessed for eligibility (n=257) 
Excluded  (n=56) 
 Not meeting inclusion criteria (n=43) 
 Excluded because stop RCT (n=13) 
Randomized (n=201) 
Analysed  (n= 81) Analysed  (n=72) 
Allocated to CAU-SF (n=99) 
 Received allocated intervention (n=72) 
 Did not receive allocated intervention (n=12) 
 Excluded because stop RCT (n=14) 
 Declined to participate (n= 1) 

Allocated to CAU (n=102) 
 Received allocated intervention (n= 81) 
 Did not receive allocated intervention (n= 5) 














Figure 2 Flow diagram
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Table 1 General characteristics of participants in the CAU and the CAU SF and participants who completed 









mean SD mean SD median IQR median IQR
Age (years) (n=153) 44 12.4 44 11.9 44.6 33.6 to 52.3 47.4 40.4 to 54.9
Average pain last week (n=153) 6 1.6 7 1.6 7 6 to 8 7 5 to 8
Worst pain last week* (n=153) 8 1.6 8 1.3 8 7 to 9 8 7 to 9
n % n % n % n %
Gender (% female) (n=153) 45 56 49 68 79 66 15 45
Duration of pain (n=131)
3 months to 1 year 15 23 20 30 27 26 8 31
> 1 year 50 77 46 70 78 74 18 69
Assigned treatment duration (weeks)
(n=153)
8 0 0 26 36 23 19 3 9
12 37 46 45 63 66 55 16 49
16 41 51 1 1 30 25 12 36
20 3 4 0 0 1 1 2 6
Marital status (n= 132)
Single 9 14 11 17 16 15 4 15
Married/ living together/LAT 53 80 47 71 77 73 23 85
Otherwise 4 6 8 12 12 12 0 0
Education (n=136)
No or low education 20 30 13 19 25 23 8 30
Middle education 30 44 34 50 51 47 13 48
High education 18 17 21 31 33 30 6 22
Work status** (n=135)
Employed, fulltime 19 27 20 31 34 32 5 18
Employed, parttime 22 32 18 27 36 34 4 14
houseman/-wife 9 13 8 12 9 8 8 29
Unemployed 8 12 8 12 12 11 4 14
Otherwise 11 16 12 18 16 15 7 25
Welfare status** (n=135)
Not working and no welfare 25 37 23 34 43 40 5 18
Partial sick leave/disability pension 30 44 30 45 40 37 20 71
Full sick leave/disability pension 6 9 9 13 14 13 1 4
unemployed 4 6 0 0 4 4 0 0
Otherwise 3 4 5 7 6 6 2 7
Pain location (n=333)
Head or face 16 9 21 13 31 12 6 8
Upper extremities 21 12 16 10 27 10 10 14
Neck or shoulders 38 22 39 24 59 23 18 25
Low back 47 28 45 27 75 29 17 24
Lower extremities 32 19 33 20 50 19 15 21
Otherwise 15 9 10 6 20 8 5 7
Number of sites (median, IQR) 2 [1,4] 2 [1,4] 2 [1,4] 3 [1,3]
CAU: Care as usual, CAU-SF: Care as usual short form * Signiﬁ cant difference between CAU and CAU-SF 
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Outcomes and estimation
The reduction of PDI scores was 2.5 larger in the CAU group compared to the CAU-SF group 
(Figure 1). The point estimate of the difference was 2.5 and lies within the non-inferiority margin 
from 0.0 to 4.0. Because the CI of this difference exceeded both the upper and the lower border 
of the non-inferiority margin, the results were inconclusive.
In 74% of the cases, PRPs were delivered per protocol or shorter, and in 26% of the cases PRPs 
were extended (Table 2: CAU-SF 36%; CAU 17%). Differences in dosage between shortened, 
dosage as planned and extended PRPs were non-signiﬁ cant (p=0.066). Reasons for extending 
were: changes in the behaviour or situation of the patient, RTW assistance needed more support 
and/or more time than anticipated, patient case was more complex than estimated a priory, and 
treatment logistics. 
Both groups improved signiﬁ cantly over time. SMD and ES for PDI and EQ5D scores are presented 
in Table 3. Differences in results were not signiﬁ cant (p>0.05) between groups for both outcome 
measures. 





P value 95% CI
Received treatment duration (weeks) 
(mean sd)
11.7 4.5 10.8 3.9 0.323 -0.525 to 2.219
Received contact hours (mean, sd) 30.7 11.3 29.8 10.4 0.622 -2.651 to 4.389
PRP Dropouts (n,%) 22 27% 11 15%
Weeks (mean, sd) 6.0 3.7 5.1 2.2
PRP Shortened (n,%)  23 29%  15 21%
Weeks (mean, sd) -5.7 4.0 -3.4 2.6
PRP As planned (n,%) 22 27% 20 28%
PRP Extended 14 17% 26 36%
Weeks (mean, sd) 2.9 2.0 4.0 2.0
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n Difference in 
means (sd) 
95% CI SMD
PDI total 144 37.0 (13.3) 119 25.8 (16.2) 112 9.6 (12.8) 7.2 to 12.0 0.8
CAU 74 36.1 (12.5) 63 25.1 (15.0) 58 10.8 (13.2) 7.3 to 14.3 0.8
CAU-SF 70 37.9 (14.2) 56 26.6 (17.7) 54 8.3 (12.2) 5.0 to 11.6 0.7
ES for between 
group difference 
0.20
EQ5D index total 125 0.55 (0.20) 101 0.70 (0.18) 93 0.13 (0.17) 0.09 to 0.17 0.8
CAU 66 0.56 (0.19) 54 0.70 (0.17) 51 0.11 (0.19) 0.06 to 0.17 0.6
CAU-SF 59 0.54 (0.21) 47 0.70 (0.20) 42 0.15 (0.15) 0.10 to 0.19 1.0
ES for between 
group difference 
-0.19
T0: before pain rehabilitation program (PRP); T1: direct after PRP.
PDI: Pain Disability Index (scale 0-70); EQ5D: Euroqol 5D index (scale 0.0-1.0),CAU: Care as usual, CAU-SF: 
Care as usual short form, SMD: Standardized mean difference; ES: Effect Size
Ancillary analyses
Further analyses were performed on differences in trial results between subgroups, patients for 
whom the PRP was delivered per protocol or shortened, and patients for whom the PRP was 
extended. The mean duration of the per protocol subgroup was 10.0 (SD 3.8) weeks. The mean 
number of contact hours was 27.1 (SD 9.7). For the extended subgroup mean duration was 
15.0 (SD 3.3) weeks, and 39.2 (SD 8.9) contact hours (Table 4). SMD of PDI of the per protocol 
subgroup was 0.9; ES of the extended subgroup was 0.6. Because the duration of the PRPs 
was similar between groups, a regression analysis was performed to analyze predictors of PRP 
results. Dependent variable was change in disability (PDI T1-T0). Independent variables were: 
PDI baseline, PRP duration (weeks) and contact hours, gender, average pain at baseline and 
interaction term of gender and duration (weeks). Dosage of PRP or any of the other variables did 
not signiﬁ cantly contribute to the regression model (results not presented).
Table 4 Differences between subgroups of patients, who completed the trial, according to duration of PRP, 
per protocol or shorter and extended
PRP per protocol or shorter PRP extended Mean Difference 95% CI P value
mean sd n mean sd n
PDI T0 37.7 12.3 77 33.0 14.0 37 4.7 0.42 to 9.79 0.07
PDI T1 26.7 16.6 71 22.8 16.2 38 3.9 -2.67 to 10.49 0.24
PDI T0-T1 10.4 10.4 68 9.4 16.0 35 1.1 -4.12 to 6.26 0.68
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Adverse events
No trial related adverse events were reported. 
Discussion
The statistical analyses showed a point estimate difference between groups of 2.5 with CI from 
-2.2 to 7.3, which means non-inferiority was inconclusive. Within both groups, short term ES 
were moderate to large for outcome measures disability and quality of life. In a quarter of all 
cases the duration of PRP could be reduced. 
Because of extension of PRP in patients randomized to CAU-SF, this study was not able to detect 
differences in dosage or effect. The results could imply that shortening of PRP duration may be 
considered in some cases, without loss of short term results. A lower dosage may beneﬁ t patients 
and other stakeholders. However, 26% of all PRPs (36% within CAU-SF and 17% within CAU) 
were extended to achieve a desired outcome. Extending (and shortening) of PRP was always 
agreed upon by the patients and the PRP team, and was a result of a difference between baseline 
needs and progress during PRP. At this point in time it is not possible to identify characteristics of 
patients whose PRPs were extended or shortened, and thus to plan a correct dosage at the start. 
This topic should be subject of further investigation. On the other hand, the results of the extended 
subgroup were similar to the per protocol group, indicating that extension of treatment might 
not be a solution to improve treatment outcome. Signiﬁ cant differences between completers and 
drop-outs may be hypothesized by less motivation of patients with disability compensation or 
housewives to complete treatment. However, characteristics of dropouts have not been subject 
of study. It is unknown whether this has systematically inﬂ uenced the results of this study.  
Because this trial is the ﬁ rst of its kind, the results of this trial cannot be compared to other pain 
rehabilitation trials with similar designs. Patient characteristics such as pain disability, pain intensity, 
pain duration, gender distribution, appear similar to other PRP trials, both in the Netherlands 
and internationally 5, and regular clinical secondary and tertiary rehabilitation programs in the 
Netherlands. Dosage of PRP in this study was ‘midrange’ when compared to dosage reported 
in other studies 14. The results of this study stress the relevance of further dosage studies in 
different settings 5. One of the main challenges expressed in pain rehabilitation is the issue of 
‘what works for whom’. We suggest adding another challenge: ‘how much works for whom?’ 
Within pain rehabilitation, this may apply to the multidisciplinary program as a whole, but also 
to its components. This question may open a new line of research that may lead to major new 
insights. Because dosage has been a methodological blind spot in PRP research, and dosage 
variables were deﬁ ned and interpreted differently across studies, results of previous trials may 
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results, it is expected that A is the treatment of choice. However, theoretically, if the dose of A 
was higher than B, the difference also might be explained by under dosage of B 15. Differences 
in dosage could also explain differences between studies and could be reasons why some studies 
were not able to detect signiﬁ cant differences between interventions 14.
Weaknesses and strengths
Weakness of the study was that it had to be discontinued prematurely because too many PRPs 
in de CAU-SF group were extended. This caused lack of contrast regarding dosage between the 
CAU and CAU-SF groups, which may explain partly the inconclusiveness of the results. In addition 
the small sample size caused wide CI, which also led to inconclusiveness.
Different scenario’s were considered and discussed with the team to shorten the program. CAU 
was offered in programs of 8,12,16 and 20 weeks. In absence of evidence, it was decided to test 
shortening of PRP with 1 step (4 weeks). This could be considered a methodological weakness 
of the study, because the relative impact differed between programs (from 12 to 8 weeks: 33% 
reduction, 12 to 16 week: 25% reduction, 20 to 16 weeks: 20% reduction). On the other hand, 
adherence to CAU strengthens this study because it reduced the risk of allocation bias in patients 
and clinicians. 
Extension of treatment duration may be regarded as a limitation or even as adverse event or 
program violation. However, during this study, we were obliged to adhere to the Dutch health 
care regulations and the Medical Ethics Committee. As a consequence, we were not allowed 
to deny health care that was deemed necessary for good patient care. Within the area of pain 
rehabilitation there are no guidelines regarding dosage of PRPs. As described in the introduction, 
PRPs aim to reduce disability and use of health care services. During PRP patients are coached to 
self manage pain and disability. As far as we know there are no published validated measures 
to assess these self management skills. Consequently, it is unclear at what point a patient will 
be ready to self manage his pain and disability, and when PRP is no longer of added value. 
Partly because of lack of evidence regarding dosage of PRP, choices of dosage of PRP are unclear 
and arbitrary. This may result in differences in dosage between and within PRP teams. This is a 
weakness of this study because, for some cases this resulted in shortening or extending of PRP 
in both the CAU and CAU-SF groups. On the other hand, this is an important reason for future 
research to focus on the rationale underlying dosage of PRP, including transparency of choices in 
dosage of treatment. This should eventually lead to more rational dosage of PRP, including explicit 
arguments on which dosage for individual patients is based. This could result in development of 
validated measurements to determine dosage of PRP. 
A strength of this study is the pragmatic, clinical design; including the struggle of clinical practice 
regarding dosage of PRPs. This study shows results of shortening and extending PRPs. Based on 
the regression analyses, which showed that dosage did not signiﬁ cantly contribute to the model, 
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was the ﬁ rst trial within pain rehabilitation to study dosage, we suggest replication in different 
settings, and that all future trials in this ﬁ eld clearly describe dosage issues to enable future 
(meta-)analyses of trial results.
In conclusion, reduction of dosage of PRP did not lead to non-inferior mean results. Because the 
CI of the mean difference exceeded both the upper and the lower border of the non-inferiority 
margin, the results of this trial are inconclusive.
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